期刊文献+

地西他滨联合CAG方案对AML老年患者免疫指标和不良反应的影响 预览

Effects of combination of decitabine and CAG on cellular immunity,humoral immune indexes and adverse reactions in elderly patients with AML
在线阅读 下载PDF
收藏 分享 导出
摘要 目的分析地西他滨联合CAG方案对老年急性髓系白血病(AML)患者细胞免疫、体液免疫指标和不良反应的影响。方法将该院94例老年AML患者作为研究对象,分为对照组(51例,单用CAG方案)和联合组(43例,地西他滨联合CAG方案),比较两组治疗效果、细胞免疫、体液免疫指标和不良反应的发生情况。结果联合组总有效率显著高于对照组(P<0.05);两组治疗后细胞免疫和体液免疫指标均显著低于治疗前(P<0.05);联合组治疗后细胞免疫指标较对照组显著降低(P<0.05),但两组治疗后的体液指标的比较差异并无统计学意义(P>0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论地西他滨联合CAG方案可有效提高老年AML患者的临床疗效,其对细胞免疫功能的阻滞作用较单用CAG方案者明显增大。 Objective To analyze the effects of decitabine combined with CAG on cellular immunity,humoral immune indexes and adverse reactions in elderly patients with acute myeloid leukemia(AML).Methods A total of 94 elderly patients with AML were enrolled in the study.They were randomly divided into the control group(51 cases,undergoing CAG)and the combination group(43 cases,receiving decitabine combined with CAG regimen).The treatment effects,cellular immunity,humoral immune indexes and adverse reactions were compared between the two groups.Results The total efficiency of the combination group was significantly higher than that of the control group(P<0.05);the cellular immunity and humoral immunity indexes of the two groups after treatment were significantly lower than those before treatment(P<0.05);the cell immunity indexes in the combination group were significantly lower than those in the control group(P<0.05),but the humoral immune indexes showed no significant difference between the two groups after treatment(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of decitabine and CAG can effectively improve the clinical efficacy of elderly patients with AML,its blocking effects on cellular immune function are obviously higher than that of single CAG therapy.
作者 沈磊 夏瑞祥 SHEN Lei;XIA Ruixiang(Department of Hematology,the First Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230032,China)
出处 《重庆医学》 CAS 2019年第8期1319-1322,1326共5页 Chongqing medicine
基金 国家自然科学基金青年科学基金培养计划项目(2013KJ15) 蚌埠医学院科技发展基金项目(BYKF16071)。
关键词 地西他滨 CAG方案 老年人 白血病 髓样 急性 免疫活性 decitabine CAG regimen aged leukemia,myeloid,acute immunocompetence
作者简介 沈磊(1977-),主治医师,本科,主要从事血液病学研究;通信作者:夏瑞祥,E-mail:13865673138@163.com。
  • 相关文献

参考文献10

二级参考文献89

  • 1秘营昌,陈雪晶,俞文娟,薛艳萍,赵耀忠,姜波,李大鹏,施均,卞寿庚,王建祥.原发性老年急性髓系白血病的特点及疗效分析[J].中华血液学杂志,2005,26(7):439-440. 被引量:3
  • 2华东FLAG方案治疗协作组,李军民,沈志祥.氟达拉滨联合阿糖胞苷和粒细胞集落刺激因子治疗复发和难治性急性髓系白血病[J].中华血液学杂志,2005,26(11):684-685. 被引量:17
  • 3邵彬,高彦荣,王椿,颜式可,蔡琦,姜杰玲,杨隽,白海涛,赵旻,赵初娴.77例老年急性髓性白血病患者的预后因素分析[J].癌症:英文版,2006,25(8):1007-1012. 被引量:7
  • 4Laubach J, Rao AV. Current and emerging strategies for the management of acute myeloid leukemia in the elderly[J]. Oncologist, 2008,13 (10) : 1097. 被引量:1
  • 5Kantarjian H,O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome[J].Cancer, 2006,106 (3) : 1090. 被引量:1
  • 6Grimwade D,Walker H, Harrison G, et al. The predictive value of hierarchical eytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial[J]. Blood, 2001,98 (5) : 1312. 被引量:1
  • 7Craig CM,Schiller GJ. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches[J].Blood Rev,2008,22(4):221. 被引量:1
  • 8Larson RA, Stone RM, Mayer RJ, et al. Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B[J].Clin Cancer Res,2006,12(11):3556s. 被引量:1
  • 9Appelbaum FR,Gundaeker H, Head DR, et al. Age and acute myeloid leukemia[J]. Blood, 2006,107 (9) : 3481. 被引量:1
  • 10Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly[J]. Arch Intern Med, 2002,162(14) : 1597. 被引量:1

共引文献143

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈